|Title:||BRCA1 gene expression in breast cancer: A correlative study between real-time RT-PCR and immunohistochemistry|
|Publisher:||Journal of Histochemistry and Cytochemistry|
|Citation:||Al-Mulla, F., Abdulrahman, M., Varadharaj, G., Akhter, N., & Anim, J. T. (2005). BRCA1 gene expression in breast cancer: A correlative study between real-time RT-PCR and immunohistochemistry. Journal of Histochemistry and Cytochemistry, 53(5), 621-629. Link to full text: http://hinari-gw.who.int/whalecomjhc.sagepub.com/whalecom0/content/53/5/621.long|
|Abstract:||Breast cancer is a major cause of cancer-related mortality in women. There are major discrepancies concerning the usefulness of various antibodies in detecting breast cancer susceptibility gene 1 (BRCA1) protein and its subcellular localization. The aim of the present study was to determine the specificity and sensitivity of immunohistochemistry (IHC) as a screening method for demonstrating BRCA1 expression. BRCA1 gene expression in archival paraffin-embedded breast cancer tissues was studied simultaneously at the protein and mRNA levels, and the two findings were compared. Forty-eight archival paraffin-embedded breast cancer tissues were studied for BRCA1 gene expression at protein level by IHC using four different antibodies against different BRCA1 epitopes and at mRNA level using real-time RT-PCR. BRCA1 mRNA expression was reduced or absent in 79% of the samples, and this finding correlated significantly with loss of BRCA1 protein expression in 83% of breast cancer tissues using one BRCA1 antibody studied (AB-1, against N-terminus epitope). The specificity of this antibody was 91.3%, and its sensitivity was 66.6%. There was no significant correlation between BRCA1 mRNA and protein expression as demonstrated by the remaining three antibodies. Antibody 8F7 had the highest sensitivity of 100%, but its specificity was 30.4% if mRNA levels were considered as the reference standard.|
|Appears in Collections:||Department of Pathology 9|
Items in UGSpace are protected by copyright, with all rights reserved, unless otherwise indicated.